FBIO on Nasdaq

Fortress Biotech

Logo: https://www.fortressbiotech.com/, Non-free logo, via Wikipedia⁵

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.³ From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

$63.3MRevenue, fiscal 2025⁶

$6.8MNet income, fiscal 2025⁶

2006Founded¹

Compare with Nuvation Bio Inc., Tango Therapeutics (United States) or Lite Strategy, Inc., or pick any stock.

TickerFBIO on Nasdaq¹
Industryhealth care¹
HeadquartersUnited States¹
Websitewww.fortressbiotech.com
Legal formDelaware corporation¹
Incorporated inDE⁷
Business address1111 Kane Concourse, Suite 301, Bay Harbor Islands, Fl 33154⁷
Filer categoryNon-accelerated filer, Smaller reporting company⁷
LEI529900DZUWSYUURECK24⁴
StatusActive⁴
LEI statusLapsed (not renewed)⁴
Registered addressc/o COGENCY GLOBAL INC., 850 NEW BURTON ROAD SUITE 201, 19904 Dover, United States⁴
Registered withDivision of Corporations, Department of State, 4183018⁴

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-111.0%Operating margin⁶

10.8%Net margin⁶

9.7%Revenue growth, 2025⁶

13.7%Return on equity⁶

1.05×Debt to equity⁶

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Qbrexza brought in 41% of the revenue Fortress Biotech broke down this way in fiscal 2025.

Qbrexza$25.0M⁶41%down 0% from 2024
Emrosi$14.7M⁶24%
Accutane$12.9M⁶21%down 34% from 2024
Foam Franchise Products$5.9M⁶10%down 12% from 2024
Other Legacy Product Revenue$2.7M⁶4%down 31% from 2024

Products and services by year

Products and services	2024	2025
Qbrexza	$25.1M	$25.0M
Emrosi	$0	$14.7M
Accutane	$19.4M	$12.9M
Foam Franchise Products	$6.7M	$5.9M
Other Legacy Product Revenue	$4.0M	$2.7M

Business segments

Journey brought in 98% of the revenue Fortress Biotech broke down this way in fiscal 2025.

Journey$61.9M⁶98%up 10% from 2024
Avenue Therapeutics, Inc$1.4M⁶2%

Business segments by year

Business segments	2024	2025
Journey	$56.1M	$61.9M
Avenue Therapeutics, Inc		$1.4M

Where the money goes

Where each dollar of revenue went, fiscal 2025

Cost of revenueSelling, general and admin

Cost of revenue17¢$20.9M
Selling, general and admin77¢$96.4M
Income tax0¢$620.0K
Profit5¢$6.8M

Out of $63.3M in revenue.⁶

Financial statements

Revenue⁹¹⁰¹¹¹²¹³¹⁴⁶$63.3M in 2025+135% since 2018

Operating income⁹¹⁰¹¹¹²¹³¹⁴⁶-$70.2M in 2025−41% since 2018

Net income⁹¹⁰¹¹¹²¹³¹⁴⁶$6.8M in 2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁶

Period ending	2025-12-31	2024-12-31
Product revenue, net	$61.2M	$55.1M
Collaboration revenue		$1.5M
Other revenue	$2.0M	$1.0M
Net revenue	$63.3M	$57.7M
Cost of goods - (excluding amortization of acquired intangible assets)	$20.9M	$20.9M
Amortization of acquired intangible assets	$4.3M	$3.4M
Research and development	$11.9M	$56.6M
Research and development - licenses acquired		$252.0K
Selling, general and administrative	$96.4M	$87.7M
Loss recovery		-$4.6M
Asset impairment	$0	$3.7M
Total operating expenses	$133.5M	$168.1M
Loss from operations	-$70.2M	-$110.4M
Interest income	$2.5M	$2.7M
Interest expense and financing fee	-$10.1M	-$13.5M
Loss on common stock warrant liabilities	-$398.0K	-$638.0K
Gain from deconsolidation of subsidiary	$27.1M	$0
Other income	$17.6M	$1.3M
Total other income (expense)	$36.7M	-$10.2M
Loss before income tax expense	-$33.5M	-$120.5M
Income tax expense (benefit)	-$620.0K	$312.0K
Net loss	-$32.9M	-$120.9M
Attributable to non-controlling interests	$39.7M	$74.9M
Net income (loss) attributable to Fortress	$6.8M	-$46.0M
Preferred A dividends declared and paid and/or cumulated, and Fortress' share of subsidiary deemed dividends	-$8.7M	-$9.9M
Net loss attributable to common stockholders	-$1.9M	-$55.9M
Net loss per common share attributable to common stockholders - basic	-$0.07	-$2.69
Net loss per common share attributable to common stockholders - diluted	-$0.07	-$2.69
Weighted average common shares outstanding - basic	27.9M shares	20.8M shares
Weighted average common shares outstanding - diluted	27.9M shares	20.8M shares

Total assets⁹¹⁰¹¹¹²¹³¹⁴⁶$185.5M in 2025+32% since 2018

Total liabilities⁹¹⁰¹¹¹²¹³¹⁴⁶$123.4M in 2025+2% since 2018

Shareholders’ equity⁹¹⁰¹¹¹²¹³¹⁴⁶$49.9M in 2025+2593% since 2018

Cash⁹¹⁰¹¹¹²¹³¹⁴⁶$79.4M in 2025+21% since 2018

Long-term debt⁹¹⁰¹¹¹²¹³¹⁴⁶$52.4M in 2025−38% since 2018

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.⁶

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$79.4M	$57.3M
Accounts receivable, net	$29.8M	$10.2M
Inventory	$9.6M	$14.4M
Prepaid expenses and other current assets	$4.9M	$7.1M
Assets held for sale	$0	$1.2M
Total current assets	$123.8M	$90.4M
Property, plant and equipment, net	$2.5M	$3.3M
Operating lease right-of-use asset, net	$12.3M	$13.9M
Restricted cash	$1.2M	$1.6M
Equity investments, at fair value	$17.7M	$2.6M
Intangible assets, net	$27.6M	$31.9M
Other assets	$401.0K	$731.0K
Total assets	$185.5M	$144.2M
Accounts payable and accrued expenses	$47.1M	$65.5M
Income taxes payable	$356.0K	$932.0K
Common stock warrant liabilities	$1.0K	$214.0K
Operating lease liabilities, short-term	$2.1M	$2.6M
Partner company installment payments - licenses, short-term	$0	$625.0K
Other current liabilities	$135.0K	$1.5M
Total current liabilities	$49.7M	$71.4M
Notes payable, long-term, net	$52.4M	$58.0M
Operating lease liabilities, long-term	$12.7M	$14.8M
Partner company redeemable perpetual preferred liability	$7.1M	$0
Other long-term liabilities	$1.4M	$1.8M
Total liabilities	$123.4M	$145.9M
Cumulative redeemable perpetual preferred stock, $0.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 3,427,138 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively, liquidation value of $25.00 per share	$3.0K	$3.0K
Common stock, $0.001 par value, 200,000,000 shares authorized, 31,364,094 and 27,908,839 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	$31.0K	$28.0K
Additional paid-in-capital	$783.9M	$763.6M
Accumulated deficit	-$734.1M	-$740.9M
Total stockholders' equity attributed to the Company	$49.9M	$22.7M
Non-controlling interests	$12.3M	-$24.4M
Total stockholders' equity (deficit)	$62.2M	-$1.6M	$1.6M
Total liabilities and stockholders' equity (deficit)	$185.5M	$144.2M
Preferred Stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	15.0M shares	15.0M shares
Preferred Stock shares designated	5.0M shares	5.0M shares
Preferred Stock, shares issued	3.4M shares	3.4M shares
Preferred Stock, shares outstanding	3.4M shares	3.4M shares
Preferred Stock, liquidation preference per share	$25	$25
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	200.0M shares	200.0M shares
Common Stock, shares issued	31.4M shares	27.9M shares
Common Stock, shares outstanding	31.4M shares	27.9M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$79.4M	$57.3M
Accounts receivable, net	$29.8M	$10.2M
Inventory	$9.6M	$14.4M
Prepaid expenses and other current assets	$4.9M	$7.1M
Assets held for sale	$0	$1.2M
Total current assets	$123.8M	$90.4M
Property, plant and equipment, net	$2.5M	$3.3M
Operating lease right-of-use asset, net	$12.3M	$13.9M
Restricted cash	$1.2M	$1.6M
Equity investments, at fair value	$17.7M	$2.6M
Intangible assets, net	$27.6M	$31.9M
Other assets	$401.0K	$731.0K
Total assets	$185.5M	$144.2M
Accounts payable and accrued expenses	$47.1M	$65.5M
Income taxes payable	$356.0K	$932.0K
Common stock warrant liabilities	$1.0K	$214.0K
Operating lease liabilities, short-term	$2.1M	$2.6M
Partner company installment payments - licenses, short-term	$0	$625.0K
Other current liabilities	$135.0K	$1.5M
Total current liabilities	$49.7M	$71.4M
Notes payable, long-term, net	$52.4M	$58.0M
Operating lease liabilities, long-term	$12.7M	$14.8M
Partner company redeemable perpetual preferred liability	$7.1M	$0
Other long-term liabilities	$1.4M	$1.8M
Total liabilities	$123.4M	$145.9M
Cumulative redeemable perpetual preferred stock, $0.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 3,427,138 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively, liquidation value of $25.00 per share	$3.0K	$3.0K
Common stock, $0.001 par value, 200,000,000 shares authorized, 31,364,094 and 27,908,839 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	$31.0K	$28.0K
Additional paid-in-capital	$783.9M	$763.6M
Accumulated deficit	-$734.1M	-$740.9M
Total stockholders' equity attributed to the Company	$49.9M	$22.7M
Non-controlling interests	$12.3M	-$24.4M
Total stockholders' equity (deficit)	$62.2M	-$1.6M	$1.6M
Total liabilities and stockholders' equity (deficit)	$185.5M	$144.2M
Preferred Stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	15.0M shares	15.0M shares
Preferred Stock shares designated	5.0M shares	5.0M shares
Preferred Stock, shares issued	3.4M shares	3.4M shares
Preferred Stock, shares outstanding	3.4M shares	3.4M shares
Preferred Stock, liquidation preference per share	$25	$25
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	200.0M shares	200.0M shares
Common Stock, shares issued	31.4M shares	27.9M shares
Common Stock, shares outstanding	31.4M shares	27.9M shares

Cash from operations⁹¹⁰¹¹¹²¹³¹⁴⁶-$65.8M in 2025−33% since 2018

Capital spending⁹¹⁰¹¹¹²¹³¹⁴$0 in 2024

Free cash flow⁹¹⁰¹¹¹²¹³¹⁴⁶-$80.2M in 2024−24% since 2018

Dividends paid¹⁰¹¹¹²¹³¹⁴⁶$664.0K in 2025

Share buybacks¹⁰¹¹$70.0K in 2020

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁶

Period ending	2025-12-31	2024-12-31
Net income (loss)	-$32.9M	-$120.9M
Depreciation expense	$403.0K	$1.0M
Loss on disposal of property and equipment	$0	$29.0K
Bad debt (recovery) expense	-$211.0K	$516.0K
Amortization of debt discount	$1.4M	$2.1M
Accretion of partner company convertible preferred shares	$0	-$737.0K
Gain on termination of partner company lease	-$394.0K	$0
Loss on extinguishment of debt	$0	$2.5M
Amortization of acquired intangible assets	$4.3M	$3.4M
Settlement of partner company payables	-$2.1M	$0
Reduction in the carrying amount of operating lease right-of-use assets	$1.9M	$2.8M
Stock-based compensation expense	$28.7M	$32.6M
Change in fair value of investment	-$15.1M	$0
Common shares issued for dividend on partner company's convertible preferred shares	$0	$114.0K
Change in fair value of partner companies' warrant liabilities	$398.0K	$487.0K
Research and development - licenses acquired, expense	$0	$250.0K
Gain from deconsolidation of subsidiary	-$27.1M	$0
Asset impairment loss	$0	$3.7M
Accounts receivable	-$19.3M	$4.5M
Inventory	$4.8M	-$4.2M
Other receivables - related party	$13.0K	-$4.0K
Prepaid expenses and other current assets	$1.5M	-$624.0K
Other assets	$330.0K	$968.0K
Accounts payable and accrued expenses	-$8.0M	-$6.4M
Income taxes payable	-$576.0K	$89.0K
Lease liabilities	-$2.2M	-$3.6M
Other liabilities	-$1.7M	$1.2M
Net cash used in operating activities	-$65.8M	-$80.2M
Acquired intangible assets	$0	-$15.0M
Proceeds from sale of property and equipment	$1.2M	$0
Net cash increase upon deconsolidation of subsidiary	$9.0M	$0
Net cash provided by (used in) investing activities	$10.1M	-$15.0M
Payment of Series A perpetual preferred stock dividends	$0	-$4.0M
Proceeds from issuance of common stock for public offering, net	$0	$17.4M
Proceeds from issuance of common stock for at-the-market offering, net	$1.0M	$3.7M
Proceeds from issuance of common stock under ESPP	$87.0K	$101.0K
Exercise of warrants for cash	$2.6M	$181.0K
Proceeds from partner companies' ESPP	$217.0K	$257.0K
Partner company's dividends declared and paid	-$664.0K	-$694.0K
Partner company's redemption of preferred shares	-$265.0K	$0
Proceeds from partner companies' equity offerings and warrant exercises, net	$61.6M	$49.7M
Proceeds from partner companies' at-the-market offering, net	$19.1M	$12.0M
Proceeds from exercise of partner company's options, net	$0	$207.0K
Repayment of Oaktree Note and debt issuance costs	-$5.6M	-$51.0M
Repayment of partner company installment payments - licenses	-$625.0K	-$1.2M
Stock and warrants issued for exchange of partner company preferred shares	$0	$341.0K
Proceeds from long-term debt, net	-$75.0K	$33.7M
Proceeds from partner company's long-term debt, net	$0	$9.9M
Net cash provided by financing activities	$77.4M	$70.6M
Net increase (decrease) in cash and cash equivalents and restricted cash	$21.8M	-$24.6M
Cash paid for interest	$7.4M	$7.2M
Cash paid for income taxes	$49.0K	$120.0K
Exchange of partner company convertible preferred shares for common shares	$0	$3.4M
Fair value of assets received by partner company in repurchase transaction	$0	$2.2M
Fair value of supplies received by partner company expensed to research and development	$0	$2.5M
Partner company accounts receivable write-off related to repurchase transaction	$0	-$7.0M
Partner company accounts payable write-off related to repurchase transaction	$0	$3.6M
Partner company's deferred purchase consideration	$0	$1.3M
Warrants issued in conjunction with debt	$1.3M	$1.1M
Unpaid research and development licenses acquired	$0	$250.0K
Lease Liabilities arising from obtaining right-of-use assets	$457.0K	$188.0K

Compare Fortress Biotech with another company

The story

The company was founded in 2006 under the name Coronado Biosciences, initially as an oncology company. In 2011, it was announced that Coronado raised $47.4 million in funding. Shortly thereafter it became a public company by registering all of its private shares as common stock. The company changed its name to Fortress Biotech in April 2015.

In November 2019, Fortress Biotech was ranked number 10 in the 2019 Deloitte Technology Fast 500 annual rankings.

From Wikipedia’s article on Fortress Biotech, shared under CC BY-SA 4.0.⁸

Leadership

Who has led Fortress Biotech, and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

President

Chief financial officer

Chief operating officer

Noah D. Beerman2012–2013

2010201520202025

Chief executive officerHarlan F. Weisman Jan 9, 2013 to Jun 21, 2013¹⁹
Chief executive officerLindsay A. Rosenwald Md. Dec 23, 2013 to now²⁰
Chief executive officerBobby W. Sandage Phd. Sep 13, 2011 to Dec 3, 2012²¹
ChairLindsay A. Rosenwald Md. Jul 19, 2019 to now²²
ChairHarlan F. Weisman Jan 9, 2013 to Jun 21, 2013¹⁹
PresidentLindsay A. Rosenwald Md. Dec 23, 2013 to now²⁰
PresidentBobby W. Sandage Phd. Sep 13, 2011 to Apr 16, 2013²¹
Chief financial officerRobyn Hunter Oct 19, 2017 to Apr 29, 2022²³
Chief financial officerLucy Lu Feb 23, 2012 to Dec 3, 2014²⁴
Chief operating officerNoah D. Beerman Jun 26, 2012 to Jun 4, 2013²⁵

Board members and other officers (21)

Exec. VC - Strategic Dev.Michael S. Weiss Feb 24, 2014 to now²⁶
SVP, Biologics OperationsGeorge Avgerinos Jun 6, 2013 to Jul 9, 2019²⁷
Chief Medical OfficerKevin Horgan Nov 6, 2013 to Nov 6, 2013²⁸
OfficerKarin M. Hehenberger Apr 25, 2012 to Jun 26, 2012²⁹
See General RemarksDale Ritter Sep 13, 2011 to Jun 4, 2013³⁰
Vice chairEric K. Rowinsky Sep 13, 2011 to Sep 13, 2011³¹
See General RemarksGlenn L. Cooper Md. Sep 13, 2011 to Dec 3, 2012³²
OfficerNoah D. Beerman Sep 26, 2011 to Jan 12, 2012³³
Board memberLucy Lu Dec 19, 2022 to now³⁴
Board memberKevin Lorenz Dec 10, 2019 to now³⁵
Board memberDov Klein Jul 17, 2015 to now³⁶
Board memberMalcolm Hoenlein Feb 24, 2014 to now³⁷
Board memberMichael S. Weiss Dec 23, 2013 to now³⁸
Board memberHarlan F. Weisman Aug 20, 2012 to Aug 20, 2012³⁹
Board memberBobby W. Sandage Phd. Sep 13, 2011 to Apr 16, 2013²¹
Board memberDavid Jonathan Barrett Sep 13, 2011 to Feb 24, 2014⁴⁰
Board memberEric K. Rowinsky Sep 13, 2011 to Jan 3, 2024³¹
Board memberGlenn L. Cooper Md. Sep 13, 2011 to Dec 3, 2012³²
Board memberJ. Jay Lobell Sep 13, 2011 to now⁴¹
Board memberJimmie Harvey Sep 13, 2011 to now⁴²
Board memberLindsay A. Rosenwald Md. Sep 13, 2011 to Apr 12, 2019⁴³

Products and brands

Subsidiaries

Fortress Bio has 10 biopharmaceutical subsidiary companies which cover a range of medical therapy areas, including potential cancer treatments and therapies for rare diseases and conditions. These subsidiaries include Aevitas Therapeutics (formed in 2017), Avenue Therapeutics (formed in 2015), Caelum Biosciences (formed in 2017), Cellvation (formed in 2016), Checkpoint Therapeutics (formed in 2015), Cyprium Therapeutics (formed in 2017), Helocyte (formed in 2015), Journey Medical Corporation (formed in 2014), Mustang Bio (formed in 2015), Tamid Bio (formed in 2017) and Baergic Bio (formed in 2019).

Products

Fortress Bio’s marketed products are developed and commercialized by its subsidiary Journey Medical Corporation. These include Targadox tablets indicated for acne, eczema emollient Ceracade, wound cream Luxamend, topical corticosteroid Triderm, topical broad-spectrum antifungal solution Exelderm, Ala-Quin topical cream for skin conditions, and Ala-Scalp hydrocortisone lotion for skin conditions.

From Wikipedia’s article on Fortress Biotech, shared under CC BY-SA 4.0.⁸

Employees over time

201634¹

Former names

Fortress Biotech, Inc.Apr 30, 2015 to Oct 1, 2026⁷
CORONADO BIOSCIENCES INCMar 5, 2008 to Apr 27, 2015⁷

Timeline

Dec 23, 2013New chief executive Lindsay A. Rosenwald Md. becomes CEO²⁰
Jan 9, 2013New chief executive Harlan F. Weisman becomes CEO¹⁹
Sep 13, 2011New chief executive Bobby W. Sandage Phd. becomes CEO²¹
2006Founded Founded¹

Filings

267 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 64 major events, 78 insider forms, 24 large holders, 81 other. The latest 20:

Oct 1, 20264 EDGAR
Oct 1, 20268-K EDGAR
Sep 1, 2026SCHEDULE 13G EDGAR
Aug 13, 202610-Q EDGAR
Aug 13, 20268-K EDGAR
Jun 24, 20264 EDGAR
Jun 23, 20268-K EDGAR
May 15, 2026SCHEDULE 13G/A EDGAR
May 14, 202610-Q EDGAR
May 14, 20268-K EDGAR
Apr 28, 2026DEFA14A EDGAR
Apr 28, 2026DEF 14A EDGAR
Apr 1, 20264 EDGAR
Mar 31, 202610-K EDGAR
Mar 31, 20268-K EDGAR
Mar 30, 20268-K EDGAR
Mar 20, 2026SCHEDULE 13D/A EDGAR
Mar 20, 20264 EDGAR
Mar 20, 20264 EDGAR
Feb 23, 20268-K EDGAR

The 267 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

25 open-market trades by officers, directors and large owners since October 2021: 23 buys and 2 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Sep 23, 2024	ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMAN	Buy	763,359	$1.84	$1.4M	Form 4
Jul 11, 2024	ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMAN	Buy	5,000	$7.48	$37.4K	Form 4
Jul 10, 2024	Jin DavidChief Financial Officer	Buy	500	$7.50	$3.8K	Form 4
Jul 9, 2024	ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMAN	Buy	5,000	$7.39	$37.0K	Form 4
Jul 8, 2024	ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMAN	Buy	5,000	$7.35	$36.8K	Form 4
Jun 28, 2024	ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMAN	Buy	20,000	$1.64	$32.8K	Form 4
May 20, 2024	Klein DovDirector	Sale	10,000	$1.89	$18.9K	Form 4
May 16, 2024	ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMAN	Buy	10,000	$1.76	$17.6K	Form 4
Jan 5, 2024	ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMAN	Buy	50,000	$2.38	$119.0K	Form 4
Nov 14, 2023	ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMAN	Buy	1,567,515	$1.70	$2.7M	Form 4
Nov 14, 2023	WEISS MICHAEL SExecutive Vice Chairman	Buy	147,058	$1.70	$250.0K	Form 4
Sep 26, 2023	ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMAN	Buy	100,000	$0.28	$28.0K	Form 4
Aug 18, 2023	ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMAN	Buy	10,000	$9.34	$93.4K	Form 4
Aug 17, 2023	ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMAN	Buy	10,000	$11.75	$117.5K	Form 4
Feb 10, 2023	WEISS MICHAEL SExecutive Vice Chairman	Buy	1,197,604	$0.84	$1.0M	Form 4
Feb 10, 2023	Rowinsky Eric KDirector	Buy	11,976	$0.84	$10.1K	Form 4
Feb 10, 2023	ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMAN	Buy	2,395,209	$0.84	$2.0M	Form 4
Feb 10, 2023	Lu LucyDirector	Buy	11,976	$0.84	$10.1K	Form 4
Feb 10, 2023	LOBELL J JAYDirector	Buy	299,401	$0.84	$251.5K	Form 4
Feb 10, 2023	Jin DavidChief Financial Officer	Buy	35,928	$0.84	$30.2K	Form 4

All 25 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

INTEGRATED CORE STRATEGIES (US) LLCSCHEDULE 13G, 1 filing Sep 1, 2026⁴⁴
HIGHBRIDGE CAPITAL MANAGEMENT LLCSCHEDULE 13G/A, 2 filings Oct 25, 2024 to May 15, 2026⁴⁵
Lindsay A. Rosenwald Md.SCHEDULE 13D/A, 4 filings Nov 21, 2023 to Mar 20, 2026⁴⁶
Nantahala Capital Management, LLCSC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 2024⁴⁷
Michael S. WeissSC 13D/A, 1 filing Nov 21, 2023⁴⁸
Daryl KatzSC 13D/A, 1 filing Feb 14, 2023⁴⁹
VANGUARD GROUP INCSC 13G/A, 2 filings Feb 10, 2022 to Feb 9, 2023⁵⁰

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 54. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Vanguard Capital Management LLC	1,037,203	$3.2M	0.0%	+71,173
Opaleye Management Inc.	890,000	$2.7M	0.2%	−152,000
Mackenzie Financial Corp	555,676	$1.7M	0.0%	New
Geode Capital Management, LLC	300,521	$919.9K	0.0%	+10,266
BlackRock, Inc.	224,782	$687.8K	0.0%	+27,697
Two Sigma Investments, LP	213,786	$654.2K	0.0%	+16,961
Bridgeway Capital Management, LLC	177,368	$542.7K	0.0%	−5,000
Vanguard Fiduciary Trust Co	166,371	$509.1K	0.0%	+23,836
HB Wealth Management, LLC	116,675	$357.0K	0.0%	−3,500
Kestra Advisory Services, LLC	116,235	$355.7K	0.0%	−13,566
State Street Corp	101,601	$310.9K	0.0%	No change
Goldman Sachs Group Inc	96,358	$294.9K	0.0%	New
Integrated Wealth Concepts LLC	90,400	$276.6K	0.0%	+45,200
Renaissance Technologies LLC	86,390	$264.4K	0.0%	−13,200
Citadel Advisors LLC	77,065	$235.8K	0.0%	−103,224
Integrated Quantitative Investments LLC	68,692	$210.2K	0.0%	New
Panagora Asset Management Inc	66,025	$202.0K	0.0%	+9,357
Northern Trust Corp	63,632	$194.7K	0.0%	−166,421
180 Wealth Advisors, LLC	61,600	$188.5K	0.0%	−2,200
UBS Group AG	52,346	$160.2K	0.0%	+37,873
Susquehanna International Group, Llp	47,002	$143.8K	0.0%	−163,743
Prelude Capital Management, LLC	41,507	$127.0K	0.0%	New
PFG Investments, LLC	36,501	$111.7K	0.0%	No change
Choreo, LLC	36,250	$110.9K	0.0%	No change
Jane Street Group, LLC	25,414	$77.8K	0.0%	−15,520

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataFortress Biotech on Wikidata
2
SEC EDGARFortress Biotech filings on SEC EDGAR
3
WikipediaFortress Biotech on Wikipedia
4
GLEIFFortress Biotech LEI record (529900DZUWSYUURECK24)
5
Wikimedia CommonsFortress Biotech logo by https://www.fortressbiotech.com/, Non-free logo
6
SEC EDGARFortress Biotech 10-K for fiscal 2025
7
SEC EDGARFortress Biotech filings on SEC EDGAR
8
WikipediaFortress Biotech on Wikipedia (revision used)
9
SEC EDGARFortress Biotech 10-K for fiscal 2018
10
SEC EDGARFortress Biotech 10-K for fiscal 2019
11
SEC EDGARFortress Biotech 10-K for fiscal 2020
12
SEC EDGARFortress Biotech 10-K for fiscal 2021
13
SEC EDGARFortress Biotech 10-K for fiscal 2022
14
SEC EDGARFortress Biotech 10-K for fiscal 2023
15
SEC EDGARFortress Biotech 10-Q for fiscal 2025
16
SEC EDGARFortress Biotech 10-Q for fiscal 2025
17
SEC EDGARFortress Biotech 10-Q for fiscal 2026
18
SEC EDGARFortress Biotech 10-Q for fiscal 2025
19
SEC EDGARHarlan F. Weisman, Chief executive officer
20
SEC EDGARLindsay A. Rosenwald Md., Chief executive officer
21
SEC EDGARBobby W. Sandage Phd., Chief executive officer
22
SEC EDGARLindsay A. Rosenwald Md., Chair
23
SEC EDGARRobyn Hunter, Chief financial officer
24
SEC EDGARLucy Lu, Chief financial officer
25
SEC EDGARNoah D. Beerman, Chief operating officer
26
SEC EDGARMichael S. Weiss, Exec. VC - Strategic Dev.
27
SEC EDGARGeorge Avgerinos, SVP, Biologics Operations
28
SEC EDGARKevin Horgan, Chief Medical Officer
29
SEC EDGARKarin M. Hehenberger, Officer
30
SEC EDGARDale Ritter, See General Remarks
31
SEC EDGAREric K. Rowinsky, Vice chair
32
SEC EDGARGlenn L. Cooper Md., See General Remarks
33
SEC EDGARNoah D. Beerman, Officer
34
SEC EDGARLucy Lu, Board member
35
SEC EDGARKevin Lorenz, Board member
36
SEC EDGARDov Klein, Board member
37
SEC EDGARMalcolm Hoenlein, Board member
38
SEC EDGARMichael S. Weiss, Board member
39
SEC EDGARHarlan F. Weisman, Board member
40
SEC EDGARDavid Jonathan Barrett, Board member
41
SEC EDGARJ. Jay Lobell, Board member
42
SEC EDGARJimmie Harvey, Board member
43
SEC EDGARLindsay A. Rosenwald Md., Board member
44
SEC EDGARINTEGRATED CORE STRATEGIES (US) LLC SCHEDULE 13G on Fortress Biotech
45
SEC EDGARHIGHBRIDGE CAPITAL MANAGEMENT LLC SCHEDULE 13G/A on Fortress Biotech
46
SEC EDGARLindsay A. Rosenwald Md. SCHEDULE 13D/A on Fortress Biotech
47
SEC EDGARNantahala Capital Management, LLC SC 13G/A on Fortress Biotech
48
SEC EDGARMichael S. Weiss SC 13D/A on Fortress Biotech
49
SEC EDGARDaryl Katz SC 13D/A on Fortress Biotech
50
SEC EDGARVANGUARD GROUP INC SC 13G/A on Fortress Biotech